Participated · Series A · Oct 2023

10 Minute School is an online education platform founded in 2015 by Ayman Sadiq and Abdullah Abyad Raied with a mission to democratise education in Bangladesh. Its product ecosystem includes an app (10ms.app), more than 25,000 classes and skills courses, and over 17,000 videos added during 2021. The company experienced rapid growth in 2021—reporting a twelvefold business increase, over 9 million new learners, 8 million learning hours delivered, and an app user base surpassing 3 million—while scaling headcount from 60 to 300. Following its $2 million seed raise from Surge (Sequoia Capital India), it plans to invest in product and technology and accelerate growth. Planned product expansions include live coaching for students in classes V–XII, test-paper courses for HSC and SSC examinees, complete admission and BCS programmes, interactive academic books for classes III–XII, and additional upskilling courses in early 2022.

Participated · Equity · Feb 2022

Day Zero Diagnostics is building a sample-to-answer diagnostic platform that couples proprietary whole genome sequencing with machine-learning analytics to rapidly detect bloodstream infections and predict antibiotic resistance within hours, eliminating the need for traditional cultures. Its technology stack includes Blood2Bac, a sample-preparation method that enriches bacterial DNA from blood, Keynome, an ML algorithm for species identification and resistance profiling, and the MicrohmDB database linking genomic data to susceptibility patterns. The company is now transitioning these technologies into an FDA-cleared and CE-marked in-vitro diagnostic instrument and disposable cartridge system. To date, Day Zero has secured more than $16 million in non-dilutive award funding from CARB-X, including an initial $6.2 million award in 2020 and a new $8.2 million option-stage award. In addition, it closed a $21 million venture equity financing in February. These funds support continued product development and regulatory preparation aimed at curbing the growing threat of antibiotic-resistant infections.

Participated · Series A · Aug 2017

MedAware provides patented, algorithm-rich software that performs real-time evaluation of prescribed drugs against up-to-date patient profiles, using advanced machine-learning algorithms that mine data from millions of EMRs to detect outliers in prescription behavior. The system immediately flags potentially life-threatening prescribing errors. The company has opened a North American headquarters in Stamford, Connecticut and earned validation from a Harvard Medical School study, with positive live-implementation results at Sheba Medical Center. MedAware plans to use new capital to develop additional ML-enabled decision-support solutions, broaden product coverage to more catastrophic error types, further establish its North American presence, and expand EMR integrations in the U.S. Financially, the Series A adds $8m in new financing and—together with prior grants and public-support awards—brings total funding to date to $12m. Led by CEO Gidi Stein, the company has multiple EMR integrations already underway. MedAware develops patent-pending big-data analytics and machine-learning technology for the medical prescription market. Its system analyzes large-scale Electronic Medical Record (EMR) data to automatically learn how physicians treat patients in real-life scenarios. The company is led by an experienced team with clinical, business and technical backgrounds. Founded in 2012 by CEO Gidi Stein, MedAware is based in Ra’anana, Israel. It plans to use the recent funding to drive initial sales to healthcare providers, insurance companies and large pharmacy chains. The raise positions the company for an early commercial push into provider and payer markets.